Figure 6.
Abundance of FA C20:3 normalized with that of FA C20:4 compared between a control and a Parkinson’s disease (PD) patient having Hoehn and Yahr [39] stage 5. Apparently, the FA C20:3 of PI 38:3 is down regulated in the PD patient.
Abundance of FA C20:3 normalized with that of FA C20:4 compared between a control and a Parkinson’s disease (PD) patient having Hoehn and Yahr [39] stage 5. Apparently, the FA C20:3 of PI 38:3 is down regulated in the PD patient.